Melanoma-associated fibroblasts in tumor-promotion flammation and antitumor immunity: novel mechanisms and potential immunotherapeutic strategies

Hum Mol Genet. 2024 Jun 21;33(13):1186-1193. doi: 10.1093/hmg/ddae056.

Abstract

Melanoma, renowned for its aggressive behavior and resistance to conventional treatments, stands as a formidable challenge in the oncology landscape. The dynamic and complex interplay between cancer cells and the tumor microenvironment has gained significant attention, revealing Melanoma-Associated Fibroblasts (MAFs) as central players in disease progression. The heterogeneity of MAFs endows them with a dual role in melanoma. This exhaustive review seeks to not only shed light on the multifaceted roles of MAFs in orchestrating tumor-promoting inflammation but also to explore their involvement in antitumor immunity. By unraveling novel mechanisms underlying MAF functions, this review aims to provide a comprehensive understanding of their impact on melanoma development. Additionally, it delves into the potential of leveraging MAFs for innovative immunotherapeutic strategies, offering new avenues for enhancing treatment outcomes in the challenging realm of melanoma therapeutics.

Keywords: CAF; antitumor immunity; immunotherapy; melanoma-associated fibroblasts; tumor-promotion flammation.

Publication types

  • Review
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Cancer-Associated Fibroblasts* / immunology
  • Cancer-Associated Fibroblasts* / metabolism
  • Fibroblasts / immunology
  • Fibroblasts / metabolism
  • Humans
  • Immunotherapy* / methods
  • Inflammation / immunology
  • Melanoma* / immunology
  • Melanoma* / pathology
  • Melanoma* / therapy
  • Skin Neoplasms / genetics
  • Skin Neoplasms / immunology
  • Skin Neoplasms / pathology
  • Skin Neoplasms / therapy
  • Tumor Microenvironment* / immunology